Checkpoint inhibitors in lung cancer: latest developments and clinical potential.

摘要: Lung cancer is the leading cause of death in United States. The vast majority patients are diagnosed with metastatic disease a 5-year survival rate less than 5%. After first-line chemotherapy or biomarker-matched targeted therapy, only suitable for small group patients, further systemic therapy options rendered very limited, if any, benefit until recently. Checkpoint inhibitors have significantly improved outcomes non-small cell lung (NSCLC) and currently an established second-line therapeutic option. In this manuscript, we review mechanism action checkpoint inhibitors, present available data approved experimental agents, discuss progress that has already been made field, as well toxicity awareness, future perspectives.